Well, as I expected and predicted in my previous post, the FDA did not waste much time approving ceftaroline (trade name – Teflaro) for complicated skin and skin structure infections (cSSSI). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm231594.htm (thanks to Lee Rogers, DPM for forwarding me …
Read more →For a number of years it was widely felt that the first of the new so-called “5th Generation”, or anti-MRSA cephalosporins would be ceftobiprole. This drug, a joint venture by the Swiss company Basilea and Johnson & Johnson had come …
Read more →Instead of a formal literature review, I just wanted to post a quick clinical comment on something that came up with a patient I saw on consultation in the hospital about 2 weeks ago. This 91 y/o female nursing home …
Read more →It is a rare study I read that makes me want to literally stop everything else I am doing and write a blog post about it. It is a dreary, gray Sunday morning and I was just catching up on …
Read more →Those of you who have read my chapter on MRSA in the 3rd Edition of the Handbook of Lower Extremity Infections (haven’t you all by now?!) or listened to me lecture about MRSA know that I am less than happy …
Read more →There is a small group of us that, when we find an interesting article dealing with infections, we pass them on so we can all be stay up to date. Some of the journals are fairly obscure and are not …
Read more →I just returned from a lecture trip to Turkey where I had the privilege of giving 5 talks, one in the Mediterranean resort city of Antalya at a nationwide Hospital Infection Congress and 4 to the faculties at various medical …
Read more →(My thanks to David Armstrong, DPM, PhD for bringing this press release to my attention) TaiGen Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing in Diabetic Foot Infection Met Primary Endpoints According to its manufacturer TaiGen, nemonoxacin, a novel, non-fluorinated quinolone has …
Read more →Two studies published in the January 7, 2010 issue of the New England Journal of Medicine have received a tremendous amount of play in the popular press. One paper out of Baylor in Houston looked at comparing chlorhexidine + alcohol …
Read more →Telavancin (Vibativ – Theravance/Astellas) is a novel lipoglycopeptide, related to vancomycin, that has been recently approved by the FDA for the treatment of complicated skin and skin structure infections (cSSSI) caused by MRSA. Telavancin now joins the ranks of vancomycin, …
Read more →